Study of faricimab for Caucasian patients with polypoidal choroidal vasculopathy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a drug called faricimab for a type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). It aims to see if the drug is safe, works well, and how long the effects last in patients who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older
- You must be of Caucasian ethnicity
- You must have a confirmed diagnosis of PCV with active polyps and bleeding or fluid in the macula of at least one eye
- Your vision in the study eye must be between 20/32 and 20/320 on an eye chart
- You cannot have had any previous treatment for PCV or other retinal diseases in the study eye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
This study tests a medicine called faricimab, which is injected into the eye to treat a certain type of wet age-related macular degeneration (type 3). The goal is to see if it can safely improve vision over the long term when doses are adjusted based on how the eye responds.
Hear when a new Polypoidal Choroidal Vasculopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.